Feasibility and preliminary clinical tolerability of low‐field MRI‐guided prostate biopsy
The Prostate · 2023-05 · 83 (7) · 656-662
DOI: 10.1002/pros.24499 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, online erschienen am 19.02.2023. Verfasst von Christina Sze und 11 weiteren Autor:innen. Beteiligte Einrichtung: New York Presbyterian - Weil Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objective
We evaluate the clinical feasibility of a portable, low‐field magnetic resonance imaging (MRI) system for prostate cancer (PCa) biopsy.
Methods
A retrospective analysis of men who underwent a 12‐core systematic transrectal ultrasound‐guided prostate biopsy (SB) and a low‐field MRI guided transperineal targeted biopsy (MRI‐TB). Comparison of the detection of clinically significant PCa (csPCa) (Gleason Grade [GG] ≥ 2) by SB and low field MRI‐TB, stratified by Prostate Imaging Reporting & Data System (PI‐RADS) score, prostate volume, and prostate serum antigen (PSA) was performed.
Results
A total of 39 men underwent both the MRI‐TB and SB biopsy. Median (interquartile range [IQR]) age was 69.0 (61.5−73) years, body mass index (BMI) was 28.9 kg/m 2 (25.3–34.3), prostate volume was 46.5 cc (32−72.7), and PSA was 9.5 ng/ml (5.5−13.2). The majority (64.4%) of patients had PI‐RADS ≥ 4 lesions and 25% of lesions were anterior on pre‐biopsy MRII. Cancer detection rate (CDR) was greatest when combining SB and MRI‐TB (64.1%). MRI‐TB detected 74.3% (29/39) cancers. Of which, 53.8% (21/39) were csPCa while SB detected 42.5% (17/39) csPCa ( p = 0.21). In 32.5% (13/39) of cases, MRI‐TB upstaged the final diagnosis, compared to 15% (6/39) of cases in which SB upstaged the final diagnosis ( p = 0.11).
Conclusion
Low‐field MRI‐TB is clinically feasible. Although future studies on the accuracy of MRI‐TB system are needed, the initial CDR is comparable to those seen with fusion‐based prostate biopsies. A transperineal and targeted approach may be beneficial in patients with higher BMI and anterior lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- New York Presbyterian - Weil Cornell Medicine, New York, New York, USA.
- New York Medical College, New York, New York, USA.
- Promaxo Inc, Oakland, California, USA.
- Mississippi Urology, Jackson, Mississippi, USA.
- Lakeland Radiologists, Jackson, Mississippi, USA.
ORCID-Profile: Bilal Chughtai
Zitieren
APA
Sze, C., Singh, Z., Punyala, A., Satya, P., Sadinski, M., Narayan, R., Nacev, A., Kumar, D., Adams, J., Nicholas, K., Margolis, D., & Chughtai, B. (2023). Feasibility and preliminary clinical tolerability of low‐field MRI‐guided prostate biopsy. The Prostate, 83(7), 656-662. https://doi.org/10.1002/pros.24499
Vancouver
Sze C, Singh Z, Punyala A, Satya P, Sadinski M, Narayan R, et al. Feasibility and preliminary clinical tolerability of low‐field MRI‐guided prostate biopsy. The Prostate. 2023;83(7):656-662. doi:10.1002/pros.24499
BibTeX
@article{Sze2023,
author = {Sze, Christina and Singh, Zorawar and Punyala, Ananth and Satya, Poorvi and Sadinski, Molly and Narayan, Ramkrishnan and Nacev, Aleksander and Kumar, Dinesh and Adams, John and Nicholas, Kathryn and Margolis, Daniel and Chughtai, Bilal},
title = {Feasibility and preliminary clinical tolerability of low‐field MRI‐guided prostate biopsy},
journal = {The Prostate},
year = {2023},
volume = {83},
number = {7},
pages = {656--662},
doi = {10.1002/pros.24499}
}
EUVIMED